Retrieve available abstracts of 117 articles: HTML format
Single Articles
June 2025
ZHAO X, Fu W Fluorodeoxyglucose (FDG) PET/CT imaging analysis and clinical treatment
evaluation in patients with SMARCA4-deficient tumors: case reports of four
patients.
J Cancer Res Clin Oncol. 2025;151:182. PubMedAbstract available
TAHERI P, Golden A A prognostic PET radiomic model for risk stratification in non-small cell lung
cancer: integrating radiogenomics and clinical features to predict survival and
uncover tumor biology insights.
J Cancer Res Clin Oncol. 2025;151:180. PubMedAbstract available
May 2025
WU KW, Deng SY, Zhang XF, Zheng DW, et al Thoracoscopy-guided thoracic paravertebral block using dexmedetomidine in
combination with ropivacaine for postoperative analgesia after thoracoscopic
radical resection of lung cancer: a randomized controlled trial.
J Cancer Res Clin Oncol. 2025;151:158. PubMedAbstract available
April 2025
WANG Z, Zeng Y, Jiang H, Luo C, et al Management strategies for primary lung carcinosarcoma: a case study and
comprehensive literature review.
J Cancer Res Clin Oncol. 2025;151:147. PubMedAbstract available
WU S, Hu C, Hu P, He W, et al RAF1 promotes anlotinib resistance in non-small cell lung cancer by inhibiting
apoptosis.
J Cancer Res Clin Oncol. 2025;151:138. PubMedAbstract available
SHIGETA N, Murakami S, Yamamoto K, Yokose T, et al Comparison of programmed death ligand-1 expression in preoperative transbronchial
lung biopsy and resected specimens in non-small cell lung cancer.
J Cancer Res Clin Oncol. 2025;151:139. PubMedAbstract available
March 2025
ZHAO QY, Liu WJ, Wang JG, Li H, et al Increasing cisplatin exposure promotes small-cell lung cancer transformation
after a shift from glucose metabolism to fatty acid metabolism.
J Cancer Res Clin Oncol. 2025;151:126. PubMedAbstract available
HUANG G, Chen L Correction: Recombinant human endostatin improves anti-tumor efficacy of
paclitaxel by normalizing tumor vasculature in Lewis lung carcinoma.
J Cancer Res Clin Oncol. 2025;151:108. PubMed
February 2025
SHENG J, Jiao J, Yan N, Pan H, et al De Novo MET-amplified NSCLC treated with savolitinib achieved remarkable tumor
regression: a case report and review of literature.
J Cancer Res Clin Oncol. 2025;151:82. PubMedAbstract available
WANG M, Zhang S, Yi D, Ou Y, et al Advances in clinical research of MET exon 14 skipping mutations in non-small cell
lung cancer.
J Cancer Res Clin Oncol. 2025;151:78. PubMedAbstract available
LI B, Wu Y, Zhang Y, Hu C, et al Global and China trends and forecasts of disease burden for female lung Cancer
from 1990 to 2021: a study based on the global burden of disease 2021 database.
J Cancer Res Clin Oncol. 2025;151:68. PubMedAbstract available
WANG M, Liu H, Zhang R, Li R, et al Small cell lung cancer with EML4-ALK fusion: report of a case responding to ALK
TKI and literature review.
J Cancer Res Clin Oncol. 2025;151:62. PubMedAbstract available
SUMINAGA K, Nomizo T, Yoshida H, Ozasa H, et al The impact of PD-L1 polymorphisms on the efficacy of immune checkpoint inhibitors
depends on the tumor proportion score: a retrospective study.
J Cancer Res Clin Oncol. 2025;151:61. PubMedAbstract available
January 2025
ENDO S, Imai H, Mouri A, Tsukamoto K, et al Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly
patients (aged >/= 75 years) with non-small cell lung cancer.
J Cancer Res Clin Oncol. 2025;151:43. PubMedAbstract available
HU M, Meng X, Wang T, Wang Y, et al Immunogenic dying cells elicit potent anti-tumor T cell immunity against lung
metastasis and tumorigenesis.
J Cancer Res Clin Oncol. 2025;151:38. PubMedAbstract available
GANESH SK, Devi CS Exploring the interactions of rapamycin with target receptors in A549 cancer
cells: insights from molecular docking analysis.
J Cancer Res Clin Oncol. 2025;151:31. PubMedAbstract available
December 2024
DAI Q, Yao X, Zhang Y, Chai Q, et al CTSG is a prognostic marker involved in immune infiltration and inhibits tumor
progression though the MAPK signaling pathway in non-small cell lung cancer.
J Cancer Res Clin Oncol. 2024;151:21. PubMedAbstract available
November 2024
RISCHKE N, Kanbach J, Haug U Age differences in the treatment of lung cancer-a cohort study among 42,000
patients from Germany.
J Cancer Res Clin Oncol. 2024;150:503. PubMedAbstract available
LI S, Yuan T, Yuan J, Zhu B, et al Opportunities and challenges of using circulating tumor DNA to predict lung
cancer immunotherapy efficacy.
J Cancer Res Clin Oncol. 2024;150:501. PubMedAbstract available
IBRULI O, Rose F, Beleggia F, Schmitt A, et al A novel mouse model recapitulating the MMR-defective SCLC subtype uncovers an
actionable sensitivity to immune checkpoint blockade.
J Cancer Res Clin Oncol. 2024;150:496. PubMedAbstract available
October 2024
LIU Y, Lin W, Gu Y, Lu C, et al Dysregulation of SIGLEC1 in non-small cell lung cancer: prognostic implications
and immunomodulatory role-a multicenter cohort study.
J Cancer Res Clin Oncol. 2024;150:481. PubMedAbstract available
MALMROS K, Kirova N, Kotarsky H, Carlsen D, et al 3D cultivation of non-small-cell lung cancer cell lines using four different
methods.
J Cancer Res Clin Oncol. 2024;150:472. PubMedAbstract available
ZUO Y, Liu Q, Li N, Li P, et al Explainable (18)F-FDG PET/CT radiomics model for predicting EGFR mutation status
in lung adenocarcinoma: a two-center study.
J Cancer Res Clin Oncol. 2024;150:469. PubMedAbstract available
YANG L, Li M, Liu Y, Jiang Z, et al Draw on advantages and avoid disadvantages: CT-derived individualized radiomic
signature for predicting chemo-radiotherapy sensitivity in unresectable advanced
non-small cell lung cancer.
J Cancer Res Clin Oncol. 2024;150:453. PubMedAbstract available
September 2024
WANG Q, Deng Z, Lu C, Chen L, et al A prospective study to compare the diagnostic accuracy of (99m)Tc-CNDG SPECT/CT
and contrast-enhanced CT in staging of non-small cell lung cancer.
J Cancer Res Clin Oncol. 2024;150:430. PubMedAbstract available
FANG Y, Wan J, Zeng Y Use machine learning to predict pulmonary metastasis of esophageal cancer: a
population-based study.
J Cancer Res Clin Oncol. 2024;150:420. PubMedAbstract available
GU G, Liu C, Zhu X, Yang Y, et al Clinical characteristics of KRAS mutation subtypes in non-small cell lung cancer
population in Xinjiang, China, and their impact on the prognosis of
immunotherapy.
J Cancer Res Clin Oncol. 2024;150:413. PubMedAbstract available
KIM SH, Seong H, Lee J, Ahn HY, et al The role of local ablative therapy in patients with advanced invasive mucinous
adenocarcinoma of the lung.
J Cancer Res Clin Oncol. 2024;150:409. PubMedAbstract available
August 2024
LI X, Lu Y, Zhao J, Yu Y, et al Savolitinib conferred sensitivity in a patient with D1228H mutation-induced
capmatinib-resistant MET exon 14 skipping mutated lung adenocarcinoma.
J Cancer Res Clin Oncol. 2024;150:395. PubMedAbstract available
UHLENBRUCH M, Kruger S Effect of TTF-1 expression on progression free survival of immunotherapy and
chemo-/immunotherapy in patients with non-small cell lung cancer.
J Cancer Res Clin Oncol. 2024;150:394. PubMedAbstract available
NGUYEN OTD, Fotopoulos I, Nost TH, Markaki M, et al The HUNT lung-SNP model: genetic variants plus clinical variables improve lung
cancer risk assessment over clinical models.
J Cancer Res Clin Oncol. 2024;150:389. PubMedAbstract available
July 2024
RATHOR A, Malik PS, Tanwar P, Khurana S, et al 'Plasma first' approach for detecting epidermal growth factor receptor mutation
in advanced non-small cell lung carcinoma.
J Cancer Res Clin Oncol. 2024;150:371. PubMedAbstract available
CHANG JX, Zhang M, Lou LL, Chu HY, et al KIS, a target of SOX4, regulates the ID1-mediated enhancement of beta-catenin to
facilitate lung adenocarcinoma cell proliferation and metastasis.
J Cancer Res Clin Oncol. 2024;150:366. PubMedAbstract available
CHEN H, Xu Y, Lin H, Wan S, et al A prognostic framework for predicting lung signet ring cell carcinoma via a
machine learning based cox proportional hazard model.
J Cancer Res Clin Oncol. 2024;150:364. PubMedAbstract available
ZHANG S, Guo C, Xu J, Qian P, et al Quantitative assessment of intertarget position variations based on 4D-CT and
4D-CBCT simulations in single-isocenter multitarget lung stereotactic body
radiation therapy.
J Cancer Res Clin Oncol. 2024;150:359. PubMedAbstract available
FOTOPOULOS I, Nguyen OTD, Nost TH, Markaki M, et al Promising microRNAs in pre-diagnostic serum associated with lung cancer up to
eight years before diagnosis: a HUNT study.
J Cancer Res Clin Oncol. 2024;150:355. PubMedAbstract available
HE L, Chen H, Ruan B, He L, et al UBQLN4 promotes the proliferation and invasion of non-small cell lung cancer cell
by regulating PI3K/AKT pathway.
J Cancer Res Clin Oncol. 2024;150:335. PubMedAbstract available
June 2024
YEGHAIAN M, Tareco Bucho TM, de Bruin M, Schmitz A, et al Can blood-based markers predict RECIST progression in non-small cell lung cancer
treated with immunotherapy?
J Cancer Res Clin Oncol. 2024;150:329. PubMedAbstract available
FENG Y, Qian R, Cui D, Luan J, et al Mutant TP53 promotes invasion of lung cancer cells by regulating desmoglein 3.
J Cancer Res Clin Oncol. 2024;150:312. PubMedAbstract available
LI Y, Wan Y, Yang X, Chen P, et al Two doses of fosaprepitant included prophylactic treatment for the three-day
cisplatin-based chemotherapy induced nausea and vomiting.
J Cancer Res Clin Oncol. 2024;150:290. PubMedAbstract available
May 2024
HUANG BT, Lin PX, Luo LM, Wang Y, et al Incorporating the inflammation-related parameters enhances the performance of the
nomogram for predicting local control in lung cancer patients treated with
stereotactic body radiation therapy.
J Cancer Res Clin Oncol. 2024;150:284. PubMedAbstract available
CHEN Z, Cai Y, Ou T, Zhou H, et al Global burden of mesothelioma attributable to occupational asbestos exposure in
204 countries and territories: 1990-2019.
J Cancer Res Clin Oncol. 2024;150:282. PubMedAbstract available
LI X, Wu D, Tang J, Wu Y, et al The efficiency and safety of temozolomide and PD-1/L1 inhibitors in pretreated
NSCLC with brain metastasis: a retrospective cohort.
J Cancer Res Clin Oncol. 2024;150:271. PubMedAbstract available
WANG X, Xu Z, Zhao S, Song J, et al A novel subtype based on driver methylation-transcription in lung adenocarcinoma.
J Cancer Res Clin Oncol. 2024;150:269. PubMedAbstract available
DANG J, Xu G, Guo G, Zhang H, et al Construction of a prognostic model for extensive-stage small cell lung cancer
patients undergoing immune therapy in northernmost China and prediction of
treatment efficacy based on response status at different time points.
J Cancer Res Clin Oncol. 2024;150:255. PubMedAbstract available
LI R, Tong R, Zhang JL, Zhang Z, et al Comprehensive molecular analyses of cuproptosis-related genes with regard to
prognosis, immune landscape, and response to immune checkpoint blockers in lung
adenocarcinoma.
J Cancer Res Clin Oncol. 2024;150:246. PubMedAbstract available
MENG X, Peng F, Yu S, Chi X, et al Knockdown of NADK promotes LUAD ferroptosis via NADPH/FSP1 axis.
J Cancer Res Clin Oncol. 2024;150:228. PubMedAbstract available
CHEN Q, Cheng J, Wang L, Lv X, et al Primary lung cancer in children and adolescents.
J Cancer Res Clin Oncol. 2024;150:225. PubMedAbstract available
April 2024
TAMURA K, Okuma Y, Nomura S, Fukuda A, et al Efficacy and safety of chemoimmunotherapy in advanced non-small cell lung cancer
patients with antibiotics-induced dysbiosis: a propensity-matched real-world
analysis.
J Cancer Res Clin Oncol. 2024;150:216. PubMedAbstract available
BILGIN B, Kuralay Y, Yucel S Prognostic importance of prognostic nutritional index and modified Glasgow
prognostic score in advanced lung cancer with targetable mutation.
J Cancer Res Clin Oncol. 2024;150:215. PubMedAbstract available
CHEN Y, Ji Y, Shen L, Li Y, et al High core 1beta1,3-galactosyltransferase 1 expression is associated with poor
prognosis and promotes cellular radioresistance in lung adenocarcinoma.
J Cancer Res Clin Oncol. 2024;150:214. PubMedAbstract available
LIU W, Zhou D, Zhang L, Huang M, et al Characteristics and outcomes of cancer patients admitted to intensive care units
in cancer specialized hospitals in China.
J Cancer Res Clin Oncol. 2024;150:205. PubMedAbstract available
WU X, Zhao X, Zhou C, Wei N, et al Prognostic and onco-immunological value of immune-related eRNAs-driven genes in
lung adenocarcinoma.
J Cancer Res Clin Oncol. 2024;150:188. PubMedAbstract available
HONG S, Lee JH, Heo JY, Suh KJ, et al Impact of concurrent medications on clinical outcomes of cancer patients treated
with immune checkpoint inhibitors: analysis of Health Insurance Review and
Assessment data.
J Cancer Res Clin Oncol. 2024;150:186. PubMedAbstract available
WANG Y, Lyu D, Cheng C, Zhou T, et al Preoperative nomogram for predicting spread through air spaces in clinical-stage
IA non-small cell lung cancer using (18)F-fluorodeoxyglucose positron emission
tomography/computed tomography.
J Cancer Res Clin Oncol. 2024;150:185. PubMedAbstract available
ZHAO R, Guan X, Zhang P, Liu Y, et al Development of postoperative bronchopleural fistula after neoadjuvant
immunochemotherapy in non-small cell lung cancer: case reports and review of the
literature.
J Cancer Res Clin Oncol. 2024;150:175. PubMedAbstract available
SAKASHITA M, Motoi N, Yamamoto G, Gambe E, et al An algorithm-based technique for counting mitochondria in cells using
immunohistochemical staining of formalin-fixed and paraffin-embedded sections.
J Cancer Res Clin Oncol. 2024;150:172. PubMedAbstract available
March 2024
JIANG L, Yang P, Liu Y, Li J, et al BRAF/MEK-targeted therapy in BRAF ex15 p.T599dup mutation-driven NSCLC: a case
report.
J Cancer Res Clin Oncol. 2024;150:162. PubMedAbstract available
BANAT M, Potthoff AL, Hamed M, Borger V, et al Synchronous versus metachronous spinal metastasis: a comparative study of
survival outcomes following neurosurgical treatment.
J Cancer Res Clin Oncol. 2024;150:136. PubMedAbstract available
GE Y, Zhan Y, He J, Li J, et al PD-(L)1 inhibitors plus bevacizumab and chemotherapy as first-line therapy in
PD-L1-negative metastatic lung adenocarcinoma: a real-world data.
J Cancer Res Clin Oncol. 2024;150:135. PubMedAbstract available
JU W, Lin L, Zhang Q, Lv X, et al GATA6 inhibits the biological function of non-small cell lung cancer by
modulating glucose metabolism.
J Cancer Res Clin Oncol. 2024;150:126. PubMedAbstract available
SHIJUBOU N, Sumi T, Kubo T, Sasaki K, et al Prognostic significance of immunohistochemical classification utilizing biopsy
specimens in patients with extensive-disease small-cell lung cancer treated with
first-line chemotherapy and immune checkpoint inhibitors.
J Cancer Res Clin Oncol. 2024;150:125. PubMedAbstract available
MA M, Luo M, Liu Q, Zhong D, et al Influence of abdominal fat distribution and inflammatory status on post-operative
prognosis in non-small cell lung cancer patients: a retrospective cohort study.
J Cancer Res Clin Oncol. 2024;150:111. PubMedAbstract available
February 2024
KRIZOVA L, Benesova I, Zemanova P, Spacek J, et al Immunophenotyping of peripheral blood in NSCLC patients discriminates responders
to immune checkpoint inhibitors.
J Cancer Res Clin Oncol. 2024;150:99. PubMedAbstract available
WANG Y, Dong A, Jin M, Li S, et al TEP RNA: a new frontier for early diagnosis of NSCLC.
J Cancer Res Clin Oncol. 2024;150:97. PubMedAbstract available
NIU L, Wu H, Gao R, Chen L, et al Optimal sequence of LT for symptomatic BM in EGFR-mutant NSCLC: a comparative
study of first-line EGFR-TKIs with/without upfront LT.
J Cancer Res Clin Oncol. 2024;150:94. PubMedAbstract available
KURIBAYASHI T, Ohashi K, Nishii K, Ninomiya K, et al Clinical characteristics of patients treated with immune checkpoint inhibitors in
EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational
registry study.
J Cancer Res Clin Oncol. 2024;150:89. PubMedAbstract available
ZHOU W, Yeerkenbieke G, Zhang Y, Zhou M, et al Guanylate binding protein 4 shapes an inflamed tumor microenvironment and
identifies immuno-hot tumors.
J Cancer Res Clin Oncol. 2024;150:90. PubMedAbstract available
XIA X, Ge Y, Ge F, Gu P, et al MAP4 acts as an oncogene and prognostic marker and affects radioresistance by
mediating epithelial-mesenchymal transition in lung adenocarcinoma.
J Cancer Res Clin Oncol. 2024;150:88. PubMedAbstract available
FAN X, Zhang Q, Qin S, Ju S, et al CircBRIP1: a plasma diagnostic marker for non-small-cell lung cancer.
J Cancer Res Clin Oncol. 2024;150:83. PubMedAbstract available
DU C, Tan L, Xiao X, Xin B, et al Detection of the DNA methylation of seven genes contribute to the early diagnosis
of lung cancer.
J Cancer Res Clin Oncol. 2024;150:77. PubMedAbstract available
WU Y, Zhang J, Zhou W, Yuan Z, et al Prognostic factors in extensive-stage small cell lung cancer patients with
organ-specific metastasis: unveiling commonalities and disparities.
J Cancer Res Clin Oncol. 2024;150:74. PubMedAbstract available
CHENG X, Zhou J, Chen Y, Zhao Y, et al Patterns and trends of mortality from metastatic colorectal cancer in Shanghai,
China from 2005 to 2021: a population-based retrospective analysis.
J Cancer Res Clin Oncol. 2024;150:68. PubMedAbstract available
January 2024
LIANG Y, Zhang X, Peng J, Liu J, et al Vitamin D-mediated tsRNA-07804 triggers mitochondrial dysfunction and suppresses
non-small cell lung cancer progression by targeting CRKL.
J Cancer Res Clin Oncol. 2024;150:51. PubMedAbstract available
ZHANG H, Lin J, Yahaya BH Comprehensive analysis of co-expressed genes with TDP-43: prognostic and
therapeutic potential in lung adenocarcinoma.
J Cancer Res Clin Oncol. 2024;150:44. PubMedAbstract available
CUI Y, Lin J, Sun D, Zhang H, et al Nomogram for predicting the overall survival and cancer-specific survival of
patients with intraductal carcinoma of the prostate.
J Cancer Res Clin Oncol. 2024;150:45. PubMedAbstract available
WANG X, He J, Li J, Wu C, et al Concordance of assessments of four PD-L1 immunohistochemical assays in esophageal
squamous cell carcinoma (ESCC).
J Cancer Res Clin Oncol. 2024;150:43. PubMedAbstract available
ZHANG J, Han W, Guo J, Zhang C, et al Efficacy of immunotherapy in HER2-mutated non-small cell lung cancer: a
single-arm meta-analysis.
J Cancer Res Clin Oncol. 2024;150:42. PubMedAbstract available
YUCE TH, Ak G, Metintas S, Dundar E, et al BAP1, Wilms' tumor 1, and calretinin in predicting survival and response to
first-line chemotherapy in patients with pleural mesothelioma.
J Cancer Res Clin Oncol. 2024;150:38. PubMedAbstract available
HUANG BT, Wang Y, Lin PX Developing a clinical-radiomic prediction model for 3-year cancer-specific
survival in lung cancer patients treated with stereotactic body radiation
therapy.
J Cancer Res Clin Oncol. 2024;150:34. PubMedAbstract available
LIU JJ, Shen WB, Qin QR, Li JW, et al Prediction of positive pulmonary nodules based on machine learning algorithm
combined with central carbon metabolism data.
J Cancer Res Clin Oncol. 2024;150:33. PubMedAbstract available
LU J, Feng Y, Guo K, Sun L, et al Prognostic value of preoperative circulating tumor DNA in non-small cell lung
cancer: a systematic review and meta-analysis.
J Cancer Res Clin Oncol. 2024;150:25. PubMedAbstract available
ZHU L, Qin J Predictive biomarkers for immunotherapy response in extensive-stage SCLC.
J Cancer Res Clin Oncol. 2024;150:22. PubMedAbstract available
MENG X, Zhao X, Zhou B, Song W, et al FSTL3 is associated with prognosis and immune cell infiltration in lung
adenocarcinoma.
J Cancer Res Clin Oncol. 2024;150:17. PubMedAbstract available
XU J, Chen H, Fan W, Qiu M, et al Plasma cell-free DNA as a sensitive biomarker for multi-cancer detection and
immunotherapy outcomes prediction.
J Cancer Res Clin Oncol. 2024;150:7. PubMedAbstract available
December 2023
BAI Y, Liu Y, Wu J, Miao R, et al CD4 levels and NSCLC metastasis: the benefits of maintaining moderate levels.
J Cancer Res Clin Oncol. 2023;149:16827-16836. PubMedAbstract available
ZHANG W, He Z, Liang F, Gong J, et al Albendazole induces an anti-tumor effect and potentiates PD-L1 blockade
immunotherapy.
J Cancer Res Clin Oncol. 2023;149:16763-16778. PubMedAbstract available
LU Y, Li Q, Xu L, Zheng Y, et al Thyroid dysfunction induced by anti-PD-1 therapy is associated with a better
progression-free survival in patients with advanced carcinoma.
J Cancer Res Clin Oncol. 2023;149:16501-16510. PubMedAbstract available
YI M, Shi J, Tan X, Zhang X, et al Integration and deconvolution methodology deciphering prognosis-related
signatures in lung adenocarcinoma.
J Cancer Res Clin Oncol. 2023;149:16441-16460. PubMedAbstract available
LIU W, Xia J, Du Q, Wang J, et al Clinico-pathological characteristics of IGFR1 and VEGF-A co-expression in early
and locally advanced-stage lung adenocarcinoma.
J Cancer Res Clin Oncol. 2023;149:16365-16376. PubMedAbstract available
MENG X, Song W, Zhou B, Liang M, et al Prognostic and immune correlation analysis of mitochondrial autophagy and
aging-related genes in lung adenocarcinoma.
J Cancer Res Clin Oncol. 2023;149:16311-16335. PubMedAbstract available
ZHANG J, Song L, Li G, Liang A, et al Comprehensive assessment of base excision repair (BER)-related lncRNAs as
prognostic and functional biomarkers in lung adenocarcinoma: implications for
personalized therapeutics and immunomodulation.
J Cancer Res Clin Oncol. 2023;149:17199-17213. PubMedAbstract available
SHIRAISHI S, Sugimoto M, Tokuuye K Salivary metabolites as novel independent predictors of radiation pneumonitis.
J Cancer Res Clin Oncol. 2023;149:17559-17566. PubMedAbstract available
November 2023
XU M, Hao Y, Shi Z, Song Z, et al Efficacy of rechallenge immunotherapy after immune monotherapy resistance in
patients with advanced non-small cell lung cancer.
J Cancer Res Clin Oncol. 2023 Nov 17. doi: 10.1007/s00432-023-05490. PubMedAbstract available
XIONG Y, Gu F, Cui J, Liu Y, et al Construction and validation of a novel prognostic nomogram for predicting overall
survival in lung adenocarcinoma patients with different patterns of metastasis.
J Cancer Res Clin Oncol. 2023;149:15039-15053. PubMedAbstract available
LV H, Shao Y, Chen QS, Song WJ, et al A case of endobronchial metastasis of colon cancer mimics sarcoidosis, and a
review of related literature.
J Cancer Res Clin Oncol. 2023;149:15287-15292. PubMedAbstract available
LIU J, Wei L Construction and validation of an efferocytosis-related prognostic signature in
lung adenocarcinoma.
J Cancer Res Clin Oncol. 2023;149:14577-14596. PubMedAbstract available
WANG Y, Yan C, Zhang C, Yu E, et al The disappearance of gastric metastasis and liver metastasis in non-small cell
lung adenocarcinoma is due to osimertinib.
J Cancer Res Clin Oncol. 2023;149:16069-16073. PubMedAbstract available
ZHOU J, Fang P, Liang Z, Li X, et al Causal relationship between lung diseases and risk of esophageal cancer: insights
from Mendelian randomization.
J Cancer Res Clin Oncol. 2023;149:15679-15686. PubMedAbstract available
ZHANG G, Guan H, Ning YL, Yao K, et al Osimertinib resistance prognostic gene signature: STRIP2 is associated with
immune infiltration and tumor progression in lung adenocarcinoma.
J Cancer Res Clin Oncol. 2023;149:15573-15588. PubMedAbstract available
MILJANIC M, Nwachukwu C, Rahimi A Definitive ablative stereotactic partial breast irradiation in early stage
inoperable breast cancer.
J Cancer Res Clin Oncol. 2023;149:15553-15559. PubMedAbstract available
CHANG Y, Xing H, Shang Y, Liu Y, et al Preoperative predicting invasiveness of lung adenocarcinoma manifesting as
ground-glass nodules based on multimodal images of dual-layer spectral detector
CT radiomics models.
J Cancer Res Clin Oncol. 2023;149:15425-15438. PubMedAbstract available
GAO R, Gao Y, Zhang J, Zhu C, et al A nomogram for predicting invasiveness of lung adenocarcinoma manifesting as pure
ground-glass nodules: incorporating subjective CT signs and histogram parameters
based on artificial intelligence.
J Cancer Res Clin Oncol. 2023;149:15323-15333. PubMedAbstract available
ZHANG L, Guan M, Zhang X, Yu F, et al Machine-learning and combined analysis of single-cell and bulk-RNA sequencing
identified a DC gene signature to predict prognosis and immunotherapy response
for patients with lung adenocarcinoma.
J Cancer Res Clin Oncol. 2023;149:13553-13574. PubMedAbstract available
October 2023
KUBO S, Kobayashi N, Matsumoto H, Somekawa K, et al Atezolizumab addition to platinum doublet: evaluating survival outcomes for
patients with extensive disease small cell lung cancer.
J Cancer Res Clin Oncol. 2023 Oct 25. doi: 10.1007/s00432-023-05457. PubMedAbstract available
MOREIRA RS, da Silva MM, de Melo Vasconcelos CF, da Silva TD, et al Siglec 15 as a biomarker or a druggable molecule for non-small cell lung cancer.
J Cancer Res Clin Oncol. 2023 Oct 16. doi: 10.1007/s00432-023-05437. PubMedAbstract available
YIN T, Liu K, Shen Y, Wang Y, et al Alteration of serum bile acids in non-small cell lung cancer identified by a
validated LC-MS/MS method.
J Cancer Res Clin Oncol. 2023 Oct 10. doi: 10.1007/s00432-023-05434. PubMedAbstract available
LI C, Zhang Y, Xia Q, Hao B, et al Multi-omics analysis revealed the mitochondrial-targeted drug combination to
suppress the development of lung cancer.
J Cancer Res Clin Oncol. 2023 Oct 2. doi: 10.1007/s00432-023-05376. PubMedAbstract available
September 2023
BRATOVA M, Skrickova J, Matusikova M, Hrabcova K, et al Effectiveness of first-line anticancer treatment may predict treatment response
in further lines in stage III/IV patients with non-small cell lung cancer.
J Cancer Res Clin Oncol. 2023 Sep 28. doi: 10.1007/s00432-023-05431. PubMedAbstract available
WU R, Zhang B, He M, Kang Y, et al MicroRNA biomarkers and their use in evaluating the prognosis of lung cancer.
J Cancer Res Clin Oncol. 2023 Sep 20. doi: 10.1007/s00432-023-05404. PubMedAbstract available
ZHAO K, Xia C, Qiu M, Yang Z, et al Lobar or sublobar resection for early-stage second primary lung cancer = 3 cm in
size: a SEER population-based study.
J Cancer Res Clin Oncol. 2023 Sep 19. doi: 10.1007/s00432-023-05396. PubMedAbstract available
HUANG F, Cui J, Wan J, Yuan X, et al SLC12A8 mediates TKI resistance in EGFR-mutant lung cancer via PDK1/AKT axis.
J Cancer Res Clin Oncol. 2023 Sep 19. doi: 10.1007/s00432-023-05416. PubMedAbstract available
ZHANG Y, Xu H, Pi S, Tan H, et al The prognostic and immunological role of FKBP1A in an integrated muti-omics
cancers analysis, especially lung cancer.
J Cancer Res Clin Oncol. 2023 Sep 16. doi: 10.1007/s00432-023-05362. PubMedAbstract available
VOORN MJJ, Bastiaansen EMW, Schroder CD, van Kampen-van den Boogaart VEM, et al A qualitative stakeholder analysis of beliefs, facilitators, and barriers for a
feasible prehabilitation program before lung cancer surgery.
J Cancer Res Clin Oncol. 2023 Sep 5. doi: 10.1007/s00432-023-05298. PubMedAbstract available
XIONG L, Zhu C, Lu Y, Chen M, et al Serum THBS2 is a potential biomarker for the diagnosis of non-small cell lung
cancer.
J Cancer Res Clin Oncol. 2023 Sep 2. doi: 10.1007/s00432-023-05330. PubMedAbstract available
DONG H, Wang X, Qiu Y, Lou C, et al Establishment and visualization of a model based on high-resolution CT
qualitative and quantitative features for prediction of micropapillary or solid
components in invasive lung adenocarcinoma.
J Cancer Res Clin Oncol. 2023;149:10519-10530. PubMedAbstract available
JIANG B, Hu L, Dong D, Guo Z, et al TP53 or CDKN2A/B covariation in ALK/RET/ROS1-rearranged NSCLC is associated with
a high TMB, tumor immunosuppressive microenvironment and poor prognosis.
J Cancer Res Clin Oncol. 2023;149:10041-10052. PubMedAbstract available